Bio-Techne subsidiary Advanced Cell Diagnostics (ACD) has introduced new BaseScope RNA in situ hybridization (ISH) assay.
The new assay, which can detect RNA transcripts at single base resolution, is commercially available as a kit through Pharma Assay Services for use in laboratories across the globe.
BaseScope holds capacity to detect exon junction/splice variants, SNPs, small insertions/deletions.
It will also detect short targets, including complex and highly homologous gene families such as MAGE and ILT in just four weeks.
Based on RNAscope technology, the BaseScope assay aggregates an advanced double Z-probe design with a novel signal amplification system to allow single-molecule detection of RNA sequences as small as 50 bases with a signal-to-noise ratio.
BaseScope assay can also be used in research areas such as neuroscience, cancer, immunology, and infectious disease.
The assay will be used in the splice variant detection, identification of antigen-specific T cell clones, detection of transduced cells in gene therapy, detection of CRISPR/Cas9 gene editing, and confirmation of knock-out/knock-in sequences.
ACD founder and president Dr Yuling Luo said: "BaseScope is a truly revolutionary assay providing groundbreaking insights into biological and disease mechanisms not possible with other technologies – again demonstrating our pioneering position in molecular pathology.
“Before the launch of the BaseScope assay, it was simply not possible to detect a specific exon-exon junction or a point mutation in situ with morphological context."
ACD is engaged in the development of cell and tissue-based research assays, as well as diagnostic tests for personalized medicine.